Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058

Tetanus Clinical Trial

Official title:

Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00548171
• Other study ID #: 110804
• Status: Completed
• Phase: Phase 4
• Start date: November 5, 2007
• Est. completion date: April 30, 2008

Study information

• Verified date: December 2019
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of repeating dTpa booster in adults 10 years after previous booster vaccination with dTpa in a previous clinical study (NCT01267058). Only subjects who received the booster vaccination in a previous clinical study are eligible for participation in this study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

No new recruitment will be performed in this booster phase (see inclusion criteria).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 203
• Est. completion date: April 30, 2008
• Est. primary completion date: April 30, 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 28 Years and older

Eligibility

Inclusion Criteria:

• Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.

• Subjects who have received dTpa vaccine or Td and pa vaccines in study 263855/002 .

• A male or female subject, recruited 10 years (+/- 9 months) after booster vaccination in study 263855/002.

• Healthy subjects as established by medical history and clinical examination before entering into the study.

• If the subject is female, she must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of booster vaccination.

• Written informed consent obtained from the subject.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.

• Administration of a vaccine not foreseen by the study protocol within 30 days prior to booster vaccination, or planned administration during the active study period

• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product

• Previous booster vaccination against diphtheria, tetanus or pertussis since the last dose received in study 263855/002

• History of diphtheria, tetanus, or pertussis diseases.

• Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination

• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.

• Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.

• Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.

• Occurrence of any of the following adverse event after a previous administration of a DTP vaccine :- hypersensitivity reaction to any component of the vaccine; - encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine; - fever = 40 °C (axillary temperature) within 48 hours of vaccination not due to another identifiable cause; - collapse or shock-like state within 48 hours of vaccination; - convulsions with or without fever, occurring within 3 days of vaccination.

• Acute disease at the time of enrolment.

• Pregnant or lactating female.

• Female planning to become pregnant or planning to discontinue contraceptive precautions.

Related Conditions & MeSH terms

• Acellular Pertussis
• Diphtheria
• Diphtheria-Tetanus-acellular Pertussis Vaccines
• Tetanus
• Whooping Cough

Intervention

Biological:
• Boostrix™
Intramuscular injection, 1 dose

Locations

Country	Name	City	State
Australia	GSK Investigational Site	Westmead	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Australia, 

References & Publications (5)

Booy R et al. The decennial administration of a reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (dTpa; BoostrixTM) in adults. Abstract presented at IDSA. Philadelphia, USA, 29 October- 1 November 2009.

Booy R, Van der Meeren O, Ng SP, Celzo F, Ramakrishnan G, Jacquet JM. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults. Vaccine. 2010 Dec 10;29(1):45-50. doi: 10.1016/j.vaccine.2010.10.025. Epub 2010 Oct 23. — View Citation

Mertsola J et al. The immunogenicity of repeated administration of reduced-antigen-content dTpa booster in adults. Abstract presented at WSPID. Buenos Aires, Argentina, 19-22 November 2009.

Mertsola J et al. The safety of repeated administration of Boostrix™, a reduced-antigen-content dTpa booster. Abstract presented at Excellence In Paediatrics (EIP). Florence, Italy, 3-6 December 2009.

Mertsola J et al. The safety of repeated administration of reduced-antigen-content dTpa boosters. Abstract presented at WSPID. Buenos Aires, Argentina, 19-22 November 2009.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations Equal to or Above (=) 0.1 International Units Per Milliliter (IU/mL)	Cut-off values defining seroprotected subjects against anti-DT/anti-TT were greater than or equal to (=) 0.1 IU/mL as assessed by the Enzyme-Linked Immunosorbent Assay (ELISA).; The analysis was performed and presents results only for subjects who in the previous study NCT01267058, had received the Boostrix™ vaccine as first booster.	One month after the booster vaccination [PI(M1)]
Secondary	Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations Equal to or Above Cut-off Values	Cut-off values, as assessed by ELISA, were greater than or equal to (=) 0.1 IU/mL and (=) 1 IU/mL.	Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Secondary	Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations	Concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).	Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Secondary	Number of Subjects With Anti-DT and Anti-TT Antibody Concentrations Equal to or Above Cut-off Values	Cut-off values, as assessed by ELISA, were greater than or equal to (=) 0.1 IU/mL and = 1 IU/mL.; This endpoint presents results for subjects included in the ATP cohort for antibody persistence.	Prior (PRE) to booster vaccination
Secondary	Anti-DT and Anti-TT Antibody Concentrations	Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).	Prior to the booster vaccination
Secondary	Number of Seronegative Subjects for Anti-DT Antibodies - ELISA	Seronegative subjects were defined as subjects with anti-DT antibody concentrations < 0.1 IU/mL prior to vaccination, as assessed by ELISA.	Prior the booster vaccination
Secondary	Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test	Sera with ELISA concentrations <0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations =0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.	Prior the booster vaccination
Secondary	Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies	Cut-off values, as assessed by ELISA, were greater than or equal to = 5 ELISA Units per millilitre (EL.U/mL) defining seropositive subjects post-vaccination.	Prior the booster vaccination
Secondary	Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations	Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL)	Prior the booster vaccination
Secondary	Number of Seronegative Subjects for Anti-DT Antibodies - ELISA.	Seronegative subjects were defined as subjects with anti-DT antibody concentrations < 0.1 IU/mL prior to vaccination, as assessed by ELISA.	Prior to the booster vaccination
Secondary	Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test.	Sera with ELISA concentrations <0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations =0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.	Prior to the booster vaccination
Secondary	Number of Seronegative Subjects for Anti-DT Antibodies - ELISA	Seronegative subjects were defined as subjects with anti-DT antibody concentrations < 0.1 IU/mL prior to vaccination, as assessed by ELISA.	One month after the booster vaccination
Secondary	Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test	Sera with ELISA concentrations <0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations = 0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.	One month after the booster vaccination
Secondary	Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies	Cut-off values, as assessed by ELISA, were greater than or equal to = 5 ELISA Units per millilitre (EL.U/mL) defining seropositive subjects post-vaccination.	Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Secondary	Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations	Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL).	Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Secondary	Number of Subjects With Booster Response to Anti-PT, Anti-FHA and Anti-PRN	Booster response was defined as appearance of antibodies in subjects who were seronegative at the pre-vaccination time point (i.e. with concentrations < 5 El.U/mL) or at least 2-fold increase of pre-vaccination antibody concentrations in subjects who were seropositive at the pre-vaccination time point (i.e. with concentrations =5 El.U/mL).	One month after the booster vaccination
Secondary	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Relationship analysis was not performed.; For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.	During the 4-day (Day 0-3) follow-up period after booster vaccination
Secondary	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Assessed solicited general symptoms were fatigue, fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)], headache, gastrointestinal symptoms [nausea, vomiting, diarrhoea and/or abdominal pain]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.; For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.	During the 4-day (Day 0-3) follow-up period after booster vaccination
Secondary	Number of Subjects With Any Unsolicited Adverse Events (AEs)	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.; For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.	During the 31-day (Day 0-30) follow-up period after booster vaccination
Secondary	Number of Subjects With Serious Adverse Events (SAEs)	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.; For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.	Following the booster vaccination

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.